Objective: To study the efficacy of surgery for recurrent cervical cancer and the influencing factors on prognosis. Methods: To retrospectively analyze the clinical data of 45 patients with recurrent cervical cancer undergoing surgical treatment in our hospital from January 1980 to October 2015, and study their clinical features and prognosis. Results: The Recurrence Free Interval (RFI) of these 45 patients was 3~120 months, and their median RFI was 15 months. Of the 45 cases, 21 recurred inside the radiotherapy field, including 18 with central recurrence and 3 with non-central recurrence; and 24 recurred outside the radiotherapy field, including 16 with pelvic recurrence who did not receive radiotherapy and 8 with distant recurrence. The overall survival time after recurrence of these 45 cases was (39.1±1.0) months, and their 2-year and 5-year survival rates were 55.6% and 22.2%, respectively. The univariate analysis showed that clinical stage, RFI, recurrent site, and initial treatment method affected the survival rate of the patients with recurrent cervical cancer (P<0.05), while the multivariate analysis revealed that recurrent site was an independent prognostic factor for recurrent cervical cancer (P=0.047). Conclusions: Appropriate surgery should be chosen for recurrent cervical cancer according to initial treatment and recurrent site. For patients with central recurrence inside their radiotherapy field, surgery is an effective treatment. Surgery is also suitable for patients without previous radiotherapy and with isolated recurrence, and adjuvant radiotherapy and chemotherapy can improve their survival.

Objective To investigate the expression of the has-miR-141 in the serum of patients with endometrial can-cer and the clinical significance. Method 55 blood samples from patients with endometrial cancer, and in the same peri-od 12 serum samples from patients with hysteromyoma were collected within 24 h before surgery, while another 5 blood samples were collected from healthy volunteers as control, then real-time quantitative PCR was used to detect the expres-sion of has-miR-141 in those specimens, and the correlation between clinical pathological risk factors and the expression of has-miR-141 in 55 cases of endometrial cancer was analyzed. Result The expression of has-miR-141 in endometrial cancer patients (2.6295±2.038) was significant higher than that in control group (1.561±0.695) (P<0.05). The expression of has-miR-141 was closely related with pathological types, lymph node metastasis and clinical staging (P<0.05). The ex-pressions in patients with non-endometrioid adenocarcinoma, lymph node metastasis and at stage III-IV were higher than those with endometrioid adenocarcinoma, without lymph node metastasis and at stage I-II. The expressions were of no sta-tistically significant difference (P>0.05) in patients with different histopathological stages, age and CA125 levels. Conclu-sion The has-miR-141 is highly expressed in the serum of patients with endometrial cancer, and is closely related with lymph node metastasis, pathological types and clinical staging, making it a promising alternative predictor in diagnosis of endometrial cancer, furthermore it may play a role in determining the progression of advanced endometrial cancer, provid-ing evidence for the early diagnosis and treatment of endometrial cancer.

肿瘤患者的个体化治疗与疗效和预后的关系日益受到重视，而完善的分子诊断技术是实现个体化治疗的基础和前提。在恶性肿瘤的风险评估、早期诊断、分子分型、肿瘤生物学行为预测、预后评估、药物筛选、疗效监测等研究和临床应用方面，分子诊断技术已体现出巨大的优势。但目前分子诊断技术在寻找卵巢癌新的治疗靶点、指导卵巢癌的靶向治疗、预测卵巢癌患者的预后及指导复发性卵巢癌的个体化治疗方面的应用研究较少，还需要进一步积累数据。

Objective To observe the clinical effect of BEV combining chemotherapy in advanced or recurrent uterine sarcomas. Method The clinical data of 4 cases of advanced or recurrent uterine sarcoma, who accepted treat-ment of BEV combining chemotherapy in our hospital from May 2006 to May 2014, were analyzed. The overall re-sponse rate (CR+PR), clinical benefit rate (CR+PR+SD), progression-free survival (PFS) and overall survival (OS), and the safety and toxicity reactions were evaluated. Results Of the four patients, one case achieved CR, with a dis-ease-free survival time of 96 months; one case achieved PR, with a PFS of 13 months, and OS was 25 months; one case achieved SD, with a PFS of 9 months, and OS was 24 months; and one case had PD, with a PFS of 3 months, and OS was 9 months. The overall response rate (CR+PR) was 50%, clinical benefit rate (CR+PR+SD) was 75%, the average PFS was 30.25 months, and the average OS was 38.5 months. Treatment-related adverse reactions were bone marrow suppression and gastrointestinal reactions. Of the four patients, one had hematologic toxicities (PLT) of grade Ⅳ, other three cases developed bone marrow suppression (WBC) of grade Ⅱ; In regard of the gastrointestinal reac-tions, 2 cases were in grade Ⅱ, the other two cases were in grade Ⅰ. Conclusion The advanced or recurrent uterine sarcoma can be effectively controlled by BEV combing chemotherapy, and the therapy was well tolerated, which is expected to be a safe and effective candidate treatment for advanced or recurrent uterine sarcoma.

Young patients with endometrium cancer have good prognosis and the five-year overall survival rate can reach 100%. But there is more than 40% of the patients are together with infertility, so it is very necessary to preserve the fertility and physiological function of young endometrial cancer patients. The most common conservative treatment to preserve fertility is the progestin therapy and the effective rate is 42%-89%, and while the successful pregnant rate could achieve to 40%-50% after the conservative treatment, What’s more, the pregnant rate could be improved to 80% above by ART assisting. However, the recurrence rate of young endometrial cancer patients who accepted conservative treatment is 40%, and that 4%-25% of the patients may have ovarian cancer at the same time. Consequently, the total hysterectomy, BSO and lymphadenectomy is suggested after the patients accomplish fertility.